生活方式控制联合纳豆红曲胶囊降低血脂的临床研究

中华养生保健 ›› 2024, Vol. 42 ›› Issue (4): 15-19.

生活方式控制联合纳豆红曲胶囊降低血脂的临床研究

于逢春¹, 周洋², 张新宇³, 范承哲⁴, 李会军⁵, 宋哲⁴, 陈志刚³, 毕齐^1,*

1.北京神经内科学会,北京,100081;
2.北京北亚中医医院内科,北京,100029;
3.北京中医药大学附属东方医院脑病科,北京,100078;
4.首都医科大学附属北京安贞医院神经内科,北京,100029;
5.北京北亚骨科医院神经内科,北京,102445

出版日期:2024-02-16 发布日期:2024-02-21
通讯作者: ^*毕齐,E-mail: biqidoctor@163.com。
作者简介:于逢春（1964—）,女,汉族,籍贯：辽宁省铁岭市,硕士研究生,主任医师,研究方向：脑血管病、睡眠障碍、神经眼科疾病。

Clinical Study on Lowering Blood Lipid Level by Lifestyle Control Combined with Nattokinase (NK) - Red Yeast Rice (RYR) Capsules

YU Feng-chun¹, ZHOU Yang², ZHANG Xin-yu³, FAN Cheng-zhe⁴, LI Hui-jun⁵, SONG Zhe⁴, CHEN Zhi-gang³, BI Qi^1,*

1. Beijing Neurology Society, Beijing 100081, China;
2. Department of internal medicine, Beijing Beiya Hospital of Traditional Chinese Medicine, Beijing 100029, China;
3. Department of encephalopathy, Dongfang Hospital Beijing University of Chinese Medicine, Beijing 100078, China;
4. Department of neurology, Beijing Anzhen Hospital Capital Medical University, Beijing 100029, China;
5. Department of neurology, Beijing Beiya Orthopedic Hospital, Beijing 102445, China

Online:2024-02-16 Published:2024-02-21

摘要/Abstract

摘要： 目的研究生活方式控制联合纳豆红曲胶囊降低血脂的有效性及安全性。方法根据纳入及排除标准募集高脂血症志愿者,按照2:1的比例随机分为纳豆红曲组（生活方式控制+纳豆红曲胶囊）20例和生活方式控制组（单纯生活方式控制）10例。两组试验期间均进行生活方式控制,纳豆红曲组同时服用崇健纳豆红曲胶囊1.35 g bid,共90 d;入组后第0天、30天、60天及90天对所有受试者进行访视,记录0 d及90 d的血脂四项、肝肾功能及各访视点的不良事件发生情况;比较分析两组试验前后血脂四项、肝肾功能变化及不良事件发生情况等。结果纳豆红曲组试验前后比较,低密度脂蛋白胆固醇（low density lipoprotein cholesterol,LDL-C）明显下降（P<0.05）;总胆固醇（total cholesterol, TC）有明显下降（P<0.05）;生活方式控制组试验前后LDL-C及TC水平比较,差异无统计学意义（P>0.05）;两组高密度脂蛋白胆固醇（High density lipoprotein cholesterol,HDL-C）各自试验前后比较,差异无统计学意义（P>0.05）;两组甘油三酯（triglyceride,TG）、谷丙转氨酶(alanine transaminase,ALT)、谷草转氨酶（aspartate aminotransferase,AST）、血肌酐（creatinine,Cr）各自试验前后比较,差异无统计学意义（P>0.05）,两组受试者试验期间均未发生不良事件。结论与单纯生活方式控制相比,对高脂血症患者予生活方式控制联合纳豆红曲胶囊干预可以有效降低LDL-C及TC水平。

关键词: 纳豆红曲胶囊, 生活方式控制, 低密度脂蛋白胆固醇, 总胆固醇

Abstract: Objective To study the efficacy and safety of lifestyle control combined with Nattokinase Red yeast rice(NK-RYR) capsules in reducing blood lipids. Methods Hyperlipidemia volunteers were recruited according to inclusion and exclusion criteria, and randomly divided into NK-RYR capsules group (lifestyle control + NK-RYR capsules) with 20 cases and lifestyle control group (lifestyle control alone) with 10 cases according to the ratio of 2:1. Lifestyle control was carried out in both groups during the experiment. The NK-RYR capsules group received Chongjian NK-RYR capsules (1.35g bid) at the same time, for a total of 90 days. All subjects were interviewed on 0 d, 30 d, 60 d and 90 d after enrollment, and the four items of blood lipids, liver and kidney function and adverse events at each site were recorded on 0d and 90d. Four items of blood lipids, changes of liver and kidney function and adverse events before and after the two groups were compared. Results Low density lipoprotein cholesterol (LDL-C) was significantly decreased in the NK-RYR capsules group before and after the test (P<0.05). total cholesterol (TC) decreased significantly (P<0.05); There was no significant difference in LDL-C and TC levels in lifestyle control group (P>0.05). There was no significant difference in High density lipoprotein cholesterol (HDL-C) between the two groups before and after each test (P>0.05). There was no significant difference in triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum creatinine before and after the trial between the two groups (P>0.05), and no adverse events occurred during the trial between the two groups. Conclusion Compared with lifestyle control alone, the combination of lifestyle control and NK-RYR capsules can reduce LDL-C and TC levels in hyperlipidemia patients.

Key words: lifestyle control, NK-RYR Capsules, LDL-C, TC

中图分类号:

R741

于逢春, 周洋, 张新宇, 范承哲, 李会军, 宋哲, 陈志刚, 毕齐. 生活方式控制联合纳豆红曲胶囊降低血脂的临床研究[J]. 中华养生保健, 2024, 42(4): 15-19.

YU Feng-chun, ZHOU Yang, ZHANG Xin-yu, FAN Cheng-zhe, LI Hui-jun, SONG Zhe, CHEN Zhi-gang, BI Qi. Clinical Study on Lowering Blood Lipid Level by Lifestyle Control Combined with Nattokinase (NK) - Red Yeast Rice (RYR) Capsules[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(4): 15-19.

参考文献

[1] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.血脂异常基层诊疗指南(实践版·2019)[J].中华全科医师杂志,2019,18(5):417-421.
[2] 中华医学会心血管病学分会,中国康复医学会心脏预防与康复专业委员会,中国老年学和老年医学会心脏专业委员会,等.中国心血管病一级预防指南[J].中华心血管病杂志,2020,48(12):1000-1038.
[3] 北京神经内科学会,纳豆激酶在血管病危险人群应用专家建议(2020版)[J].中国老年保健医学,2022,20(1):3-8.
[4] CHEN H, CHEN J, ZHANG F, et al.Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants[J]. Front Cardiovasc Med,2022,9:964977.
[5] 中国老年学和老年医学学会心脑血管病专业委员会,血脂康(胶囊)临床应用中国专家共识组.血脂康(胶囊)临床应用中国专家共识(2017修订版)[J].中华内科杂志,2018,57(2):97-100.
[6] 中国心脏联盟,中国康复医学会心脏预防与康复专业委员会,脂必泰胶囊临床应用中国专家共识组.脂必泰胶囊临床应用中国专家共识[J].中华内科杂志,2017,56(8):628-632.
[7] CICERO A F G, COLLETTI A, BAJRAKTARI G, et al. Lipid-lowering nutraceuticals in clinical practice : position paper from an International Lipid expert Panel[J]. NUTR REV,75(9):731-767.
[8] MACIEJ BANACH, ALBERICO L, CATAPANO, ARRIGO F.G. CICER, et al. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel[J]. PHARMACOL RES,183:106370.
[9] 国家心血管病专家委员会心血管代谢医学专业委员会.基层血脂管理适宜技术中国专家建议(2022 版)[J].中国循环杂志,2022.37(12):1181-1185.
[10] 《动脉粥样硬化性心血管疾病患者降胆固醇药物治疗管理专家共识》编写组.动脉粥样硬化性心血管疾病患者降胆固醇药物治疗管理专家共识[J].临床药物治疗杂志,2023,21(2):7-16.
[11] BROWN C J, CHANG L S, HOSOMURA N, et al.Assessment of Sex Disparities in Nonacceptance of Statin Therapy and Low-Density Lipoprotein Cholesterol Levels Among Patients at High Cardiovascular Risk[J]. JAMA Netw Open,2023,6(2):e231047.
[12] 国家食品药品监督管理局.关于以红曲等为原料保健食品产品申报与审评有关事项的通知[EB/OL]. 2010-1-5[2010-1-11]http://www.gov.cn/gzdt/2010-01/11/content_1507641.htm.
[13] NIEMELä O, BLOIGU A, BLOIGU R.et al.Impact of Physical Activity on the Characteristics and Metabolic Consequences of Alcohol Consumption: A Cross-Sectional Population-Based Study[J]. Int J Environ Res Public Health,2022,19(22):15048.
[14] XIONG X, WANG P, LI X, et al.The Effects of Red Yeast rice Dietary Supplement on Blood Pressure, Lipid Profile, and C-Reactive Protein in Hypertension: A Systematic Review[J]. Crit. Rev. Food Sci. Nutr,2017, 57(9):1831-1851.
[15] SUNGTHONG B, YOOTHAEKOOL C, PROMPHAMORN, et al. Efficacy of Red Yeast rice Extract on Myocardial Infarction Patients with Borderline Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials[J]. Sci. Rep,2020,10(1):2769.
[16] YUAN R, YUAN Y, WANG L, et al.Red Yeast Rice Preparations Reduce Mortality, Major Cardiovascular Adverse Events, and Risk Factors for Metabolic Syndrome: A Systematic Review and Meta-analysis[J]. Front Pharmacol,13:744928.
[17] RAHMANI P, MELEKOGLU E, TAVAKOLI S.et al.Impact of red yeast rice supplementation on lipid profile: a systematic review and meta-analysis of randomized-controlled trials[J]. Expert review of clinical pharmacology,2023,16(1):73-81.
[18] 中国血脂管理指南修订联合专家委员会.中国血脂管理指南(2023年)[J].中国循环杂志,2023,38(3):237-269.